A new generation of high potency veterinary cancer medications and nutraceuticals for pets
PetLife Announces Its All-Natural “Cancer Cocktail” with Applicability to Pet and Human MarketsThe Company may be the first to offer an all-natural “cancer cocktail” combining the therapeutic benefits of the plant and animal kingdoms.
PetLife's new patent-pending formulation has created a 'cancer cocktail' combining both Blue Scorpion Venom Chlorotoxin with plant-based phytonutrients. Preliminary testing has shown inhibition against certain cancer cell line studies without toxicity. Across the world, researchers have recognized that many cells which cause disease, have the ability to become resistant to treatment when only one drug is used. Combination therapy is increasing, recommended for the treatment of both neoplastic (cancer) and infectious disease. The 'HIV Cocktail', which changed the world's approach to the treatment of HIV, is a similar approach comparison. PetLife's new 'cancer cocktail' may prove to be the non-toxic alternative to the harmful and sometimes deadly side effects of radiation and chemotherapy. The patent pending formulation of PetLife's new 'cancer cocktail' has the curious ability to bind selectively to cancer cells and inhibit their growth demonstrating little to no side effects to the patient.
Applying science to discover therapies that significantly improve and extend pets lives.How many companion animals are diagnosed with cancer each year?
It is estimated that 70-80 million dogs and 74-96 million cats are owned in the United States.
Every day 10,000 dogs and 6,000 cats are diagnosed with cancer.
Featured Press Releases
June 14, 2017 PetLife Announces Its All-Natural “Cancer Cocktail” with Applicability to Pet and Human Markets
The Company may be the first to offer an all-natural “cancer cocktail” combining the therapeutic benefits of the plant and animal kingdoms.
HANCOCK, MD — June 14, 2017 — PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, reports on its solution to the ever increasing problem of drug resistance and high toxicity in the treatment of cancer in pets and humans. Each year, in the U.S. alone, more than eleven million cases of cancer in dogs and cats are reported, a number that continues to increase annually.
June 6, 2017 PetLife Completes Its TV Commercial for Newly Acquired Dr. Geoff’s by PetLife, Preparing for Regional Launch
Press Release (ePRNews.com) – Hancock, MD – Jun 06, 2017 – PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high-potency veterinary cancer medications and nutraceuticals for pets, announced today that its wholly owned subsidiary, Dr. Geoff’s by PetLife, Inc. (“Dr. Geoff’s by PetLife”), PetLife’s product line of natural pet food, supplements, and treats, has initiated its comprehensive product rollout.
Click here to VIEW ALL PRESS RELEASE INFORMATION
Important Facts to Know
• Cancer is the #1 disease related cause of death in dogs in the US
• Cancer accounts for almost 50% of deaths in pets older than 10 years old
• Conventional treatment can cost SEVERAL thousands of dollars, forcing pet owners to watch their pet slowly deteriorate
New frontier in pet oncological treatment utilizing the venom of the Blue ScorpionPetLife Pharmaceuticals is introducing a new breakthrough pet cancer drug that is anticipated to begin FDA trials in the upcoming months. The drug is an all-natural compound. The FDA trials are estimated to take approximately 18-24 months. PetLife Pharmaceuticals, Inc. is a publicly traded company. The stock symbol is PTLF on the OTCQB market. PetLife is a new biotech company developing products to address disease in our companion pets.
- Loading stock data...